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To enhance the intracellular delivery potential of plasmid DNA using nonviral vectors, we used polybutyl cyanoacrylate (PBCA)
and chitosan to prepare PBCA nanoparticles (NPs) by emulsion polymerization and prepared NP/DNA complexes through the
complex coacervation of nanoparticles with the DNA. The object of our work is to evaluate the characterization and transfection
eﬃciency of PBCA-NPs. The NPs have a zeta potential of 25.53mV at pH 7.4 and size about 200nm. Electrophoretic analysis
suggested that the NPs with positive charges could protect the DNA from nuclease degradation and cell viability assay showed
that the NPs exhibit a low cytotoxicity to human hepatocellular carcinoma (HepG2) cells. Qualitative and quantitative analysis of
transfection in HepG2 cells by the nanoparticles carrying plasmid DNA encoding for enhanced green ﬂuorescent protein (EGFP-
N1)wasdonebydigitalﬂuorescenceimagingmicroscopysystemandﬂuorescence-activatedcellsorting(FACS).Qualitativeresults
showed highly eﬃcient expression of GFP that remained stable for up to 96 hours. Quantitative results from FACS showed that
PBCA-NPs were signiﬁcantly more eﬀective in transfecting HepG2 cells after 72 hours postincubation. The results of this study
suggested that PBCA-NPs have favorable properties for nonviral delivery.
Copyright © 2009 Jinghua Duan et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Hepatocellular carcinoma (HCC) is a liver cancer prevalent
in Asia, especially in the Mainland China [1, 2]. As an
established human hepatocarcinoma cell line with epithelial
morphology, HepG2 cells are used routinely for a variety of
biochemical and cell biological studies [3–5].
The barrier to gene delivery, nuclease degradation in
the lysosomal compartment, has been the focus of many
investigators. Important research has been moving toward
the development of polycation-based gene-delivery systems
(such as polylysine conjugates) designed to minimize nucle-
asedegradationthroughthedesignofvectorswiththecapac-
ity to escape the endosomal-lysosomal pathway [6–8]. Behr
and others introduced the concept of the “proton sponge”
and hypothesized that polymers with buﬀering capacities
between 7.2 and 5.0, such as polyethylenimine (PEI) and
imidazole-containing polymers, could buﬀer the endosome
and potentially induce its rupture. Protein-expression levels
mediated by the polycationic proton-sponge polymer, PEI,
were at least 10-fold greater than polylysine alone [9–12].
However, protein expression after delivery of plasmid DNA
to the cell nucleus depends on the processes of transcrip-
tion and translation. Cytotoxic gene-delivery systems may
compromise these processes and potentially limit protein
expression. These situations are perhaps the most prevalent
in the nonviral polycationic gene-delivery class in which
the polycationic nature of the delivery system can lead to
cytotoxicity. To drive gene therapy ultimately into the clinic,
improved delivery systems, or vectors, must deliver DNA to
the cell in a transcriptionally active form and must fulﬁll all
regulatory agency mandates to be considered safe for use in
humans [13–16].
PBCA particles are extensively investigated for gene
and drug delivery, but now most investigated stabilizers
for PBCA lead to negatively charged particles [17]. In an2 Journal of Biomedicine and Biotechnology
attempt to provide a positive charge to a colloidal system,
chitosan has been used in the preparation and stabilization
of polyester nanocapsules [18, 19], nanoparticles [20],
submicron-sized emulsions [18], microcapsules [21], and
liposome [22]. Chitosan is a cationic high-molecular-weight
heteropolysaccharide composed mainly of b-(1,4)-2-deoxy-
2-amino-D-glucopyranose units and partially of b-(1,4)-2-
deoxy-2-acetamido-D-glucopyranose. Because of favorable
biological properties such as biodegradability, biocompati-
bility, and nontoxicity, chitosan has attracted great attention
in pharmaceutical and biomedical ﬁelds [23–28]. Chitosan
also increases the transcellular and paracellular transport
across epithelium [29].
The aim of the study was to develop positively charged
polybutyl cyanoacrylate (PBCA)-NPs in the presence of
chitosan for the potential use as a targeting gene delivery
system. Physicochemical characteristics of the prepared
nanoparticles were examined by dynamic light scattering,
transmission electron microscopy, and Fourier transform
infrared (FT-IR) spectroscopy. The transfection eﬃciency of
the prepared NPs into HepG2 cells was examined in vitro
using digital ﬂuorescence imaging microscopy system and
ﬂuorescence-activated cell sorting (FACS).
2.MaterialsandMethods
2.1.Materials. Chitosan(degreeofdeacetylation =90%)was
purchased from (Shanghai Bio Life Science & Technology
Co., Ltd. Shanghai, China). Butyl cyanoacrylate (BCA)
monomer was synthesized by (Guangzhou Baiyun Medical
Adhensive Co., Ltd. Guangzhou, China). HepG2 cell lines
were provided by ourselves. All other chemicals used were
of analytical reagent grade and without further puriﬁcation.
Ultrapure water was used for the preparation of all solutions.
2.2. PBCA Nanoparticles. PBCA-NPs were prepared by
emulsion polymerization as described in detail elsewhere
[30–35]. Brieﬂy, the desired amount (100μL) of BCA
monomer was dropped into an acidic solution of chitosan
adjusted with 1mol/L hydrochloric acid at room tempera-
ture, pH 1.5, under constant magnetic stirring, stirring was
maintained for at least 6 hours until the polymerization was
complete. The colloidal suspension obtained was brought to
pH value of 5.5 by adding 0.5mol/L NaOH.
2.3. Fourier Transform Infrared (FT-IR) Spectrometer. FT-IR
spectra were recorded on a spectrophotometer TENSOR 27
(Bruker, Billerica, Mass, USA). Test samples used for the FT-
IR analysis ﬁrst were dried and ground into a powder. The
powder then was mixed with KBr and pressed into a disk.
The samples were scanned from 400–4000cm−1.
2.4. Particle Size and Zeta Potential. T h es i z eo fP B C A -
NPs was assessed using a dynamic light scattering spec-
trophotometer Zetasizer 1000HSA (Malvern Instruments
Ltd., Worcestershire, UK). The colloidal suspension of the
NPs was diluted with deionized distilled water, and the
particle size analysis was carried out at a scattering angle of
90◦Ca n dat e m p e r a t u r eo f2 5 ◦C.
T h ez e t ap o t e n t i a lw a sm e a s u r e do nZ e t a s i z e rN a n o
system (Malvern Instruments Ltd., Worcestershire, UK). The
measurement was done in 10mmol/L NaCl using disposable
zeta cells using the general purpose protocol at 25◦C. The
instrument was calibrated routinely with a −50mV latex
standard. The mean zeta potential was determined using
phase analysis light scattering technique.
2.5. Transmission Electron Microscopy (TEM) Observation.
Particle morphology of PBCA-NPs was observed by trans-
missionelectronmicroscopy(TEM)usingaHitachiH-600at
50kV. 1mL dispersion was diluted with 1mL demineralized
water and a drop of it was placed onto a collodion
support on copper grids (200mesh). About 2 minutes of
deposition, the grid was tapped with a ﬁlter paper to remove
surface water and negatively stained by using a sodium
phosphotungstate for 5 seconds. The grid was allowed to
dry further for 10minutes and was then examined with the
electron microscope.
2.6. Preparation of NP/DNA Complexes. EGFP-N1 driven by
immediate early promoter of cytomegalovirus (CMV) was
purchased from (Clontech Laboratories, Palo Alto, Calif,
USA). The plasmids were propagated in Escherichia coli,
extracted by the alkali lysis technique [36], and puriﬁed by
an EZ-10 Spin Column Plasmid Mini-Preps kit (Bio Basic
Inc, Calif, USA) according to the manufacturer’s instruction.
DNApuritywasdeterminedbymeasuringtheopticaldensity
(OD), and DNA with OD260/OD280 ≥ 1.8 was used.
NP/DNA complexes were prepared through the complex
coacervation of the cationic polymer (PBCA-NPs) with the
EGFP-N1 plasmid. Microliters of pDNA (100μg/mL) were
added into PBCA-NPs solution, which had been ﬁltrated
through a 0.45μm ﬁlter and mixed with them in 10mmol/L
phosphate buﬀer (pH 7.4). The mixed liquor was standing
for 30 minutes at room temperature and the complexes were
used for further study. Complexes formation was conﬁrmed
by electrophoresis on a 1.0% agarose gel with TBE buﬀer
(89mmol/LTris,89mmol/Lboricacid,and2mmol/LEDTA
pH 8.0) at 75V for 90 minutes. DNA was visualized by
staining gels with ethidium bromide (0.5μg/μL). Images
were acquired using an UV transilluminator (VILBER
LOURMAT, France).
2.7. Stability of NP/DNA Complexes. Nanoparticles suspen-
sion or naked DNA was incubated with 4μL DNase I
(1U/μL) in DNase I Buﬀer, which consisted of 100mmol/L
Tris-HCl, 25mmol/L MgCl2, and 1mmol/L CaCl2 at 37◦C
for 1hours. Samples of naked DNA, undigested and digested
complexes were loaded onto a 1.0% agarose gel in Tris-
borate EDTA buﬀer at pH 8.0. The samples were run on the
gel at 75V for 90 minutes; the gel was stained with ethidium
bromide (0.5μg/μL).
2.8. Cell Uptake Study. HepG2 cells were incubated in
Dulbecco’s modiﬁcation of eagle’s medium (DMEM, Beijing
Solarbio Science & Technology Co., Ltd, Beijing, China) atJournal of Biomedicine and Biotechnology 3
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Figure 1: (A) Fourier transform IR spectra of chitosan; (B)
chitosan-coated PBCA-NPs; (C) PBCA-NPs.
37◦C, 5% CO2 with 10% fetal bovine serum (FBS) and
100U/mL penicillin-streptomycin.
A conﬂuent layer of approximately 8000 HepG2 cells
per well was incubated with 20 microliters ﬂuorescent NP
suspension, the ﬁnal concentration of NPs in the serum-
free medium was 210μg/mL, in the 6-well black plates at
37◦C. After 6 hours of incubation, the cells were washed
three times with cold PBS (pH 7.4) to eliminate excess
particles which were not entrapped by the cells. The uptake
of NPs by the HepG2 cells was examined with ﬂuorescence
microscopy Leica DM LB2 (Leica Microsystems Wetzlar
GmbH, Germany). In the control experiment, there were no
ﬂuorescent NPs in the medium.
To preparing for ﬂow cytometry, after digested with the
lyse solution containing 0.25% trypsin, the cocultivated cells
were harvested and rinsed with cooled D-Hank’s solution
and centrifuged (1000rpm, 5 minutes) to discard cell
fragments. The cells were further washed three times with
PBS and centrifuged (1000rpm, 5 minutes) to remove the
uncombined nanoparticles. The obtained cells were diluted
to single-cell suspension stabilized with 1% formaldehyde
at 4◦C. Processed single-cell suspensions were analyzed on
an FACS Calibur ﬂow cytometer (BD, Franklin Lakes, NJ,
USA) using a 488nm argon laser and FL1 bandpass emission
(530 ± 20nm) for the green ﬂuorescence. HepG2 cells were
g a t e db ys i d e w a r ds c a t t e rv e r s u sf o r w a r ds c a t t e r( S S C / F S C )
plots. Fluorescence measurements were done in the FL1
channel.
2.9. Cytotoxicity Evaluation by MTT Assay. Cytotoxicity of
the NPs was determined by (3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide) MTT assay in HepG2
cells. This assay is based on the ability of living cells to
reduce a water-soluble yellow dye, MTT, to a purple colored
water-insoluble formazan product by mitochondrial enzyme
succinate dehydrogenase. The cells were maintained in
DMEM supplemented with 10% FBS in 5% CO2 incubator
at 37◦C. Eight thousand cells were seeded per well in 96-well
microtiter plates followed by incubation for 24 hours. The
growth medium was replaced with a fresh one containing
0.1–8.0μg/μL NPs. After 24-hour incubation, 20μLo fM T T
solution (5mg/mL in PBS, pH 7.4) was added to cells
followed by further incubation for 4 hours. Thereafter, the
media was removed and cells were rinsed with PBS. The
formazan crystals formed were dissolved using dimethyl
sulfoxide (DMSO) (150μL/well) and absorbance was read at
570nm on a multiskan spectrum (Electro Thermo, Milford,
Mass, USA). Cell viability was determined as a percentage of
the negative control (untreated cells).
2.10. In Vitro Transfection. For the qualitative analysis of
transfection, HepG2 cells were grown in 6-well culture plates
containing a Corning circular glass cover-slip with seeded
1×105 cellsseededperwellandincubateduntilthecoverrate
reached 60–80%. The NP/DNA complexes were dispersed
in serum-free medium and untreated cells were used as a
negative control. After ﬁltration, the NP/DNA complexes
were added at a concentration equivalent to 2μg of EGFP-
N1 plasmid DNA per well, and incubated with the cells at
37◦C and 5% CO2 atmosphere for 6 hours. The culture
was removed from each well and replaced with regular
growth medium including 10% FBS. The cover slips were
washed three times with PBS at 96 hours posttransfection
and mounted on to microscopic slides containing a drop of
antifade mounting medium (Beyotime Institute of Biotech-
nology, Shanghai, China). The expression of GFP in the cells
was observed by a ﬂuorescence microscope.
For the quantitative analysis of transfection, HepG2 cells
were grown to semiconﬂuence in a 6-well cell culture plate
and transfected with EGFP-N1 plasmid DNA encapsulated
PBCA-NPs and compared with cells treated with serum-
free media alone. The NP/DNA complexes were dispersed
in serum-free media and added to each of the six wells at a
concentration of 2μg of plasmid DNA per well. The cells are
allowed to incubate for a period of 6 hours at 37◦Ci na5 %
CO2 incubator and then replaced by fresh growth medium.
The adherent cells are trypsinized at time intervals of 24,
48, 72, and 96 hours postincubation, centrifuged, and ﬁxed
with100μL of 4% formalin buﬀersolution. The ﬂuorescence
of the GFP produced in the transfected cell was detected
by a ﬂow cytometer equipped with an argon 488 laser. The
FL1 channel was used to detect the cells expressing GFP
ﬂuorescence.
3. Results and Discussion
3.1. Preparation and Characterization of PBCA-NPs. We
synthesized the nanoparticles by dropping monomer into an
acidic solution of chitosan. We obtained uniform particles
by adding BCA monomer, pH 1.5, at room temperature, to
0.5% (w/v) chitosan during high-speed vortexing.
FT-IR analysis was performed to conﬁrm the chitosan-
graft-PBCA. Figure 1 shows a comparison between the FT-
IR spectra of chitosan(A), chitosan-coated PBCA(B), and
PBCA(C). After chitosan-stabilized NPs had been extracted,
the residue still possessed a -CN stretch (2253.84cm−1)
and a carbonyl stretch (1752.93cm−1) corresponding to
those of PBCA and a hydrogen-bonded OH stretch
(3461.64cm−1)correspondingtothatofchitosan.Theamide
band at 1640.57cm−1that was observed in chitosan shifts
to 1635.89cm−1. These observations suggest that chitosan,
especially the NH2 group, may initiate the BCA monomer4 Journal of Biomedicine and Biotechnology
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Figure 2: (a) Size distribution and (b) zeta potential of the prepared chitosan-coated PBCA-NPs.
1μm
Figure 3: Transmission electron micrograph of the prepared
chitosan-coated PBCA nanoparticles.
in the acidic polymerization medium, leading to chitosan
chemically coupled to PBCA to form chitosan-stabilized
NPs.
The size distribution and zeta potential of the NPs
in NaCl solution were investigated by dynamic light scat-
tering. Dynamic size distribution and zeta potential may
play important roles in determining the fate of NPs after
administration [37]. Figure 2(a) shows a unimodal particle
size distribution (number average) between 100 and 200nm.
It was reported that large particles hardly reach the cells
[38], while smaller particles tended to accumulate in the
tumor sites due to the enhanced permeability and retention
(EPR) eﬀect and a greater internalization was also observed
[6]. Additionally, gene carriers with a diameter larger than
200nm are readily scavenged nonspeciﬁcally by monocytes
and the reticuloendothelial system [39].
The results of Figure 2(b) indicated that PBCA-NPs
carry positive charge with a zeta potential of about 25mV.
PBCA-NPs have a very negative zeta potential because of
the adsorption of anions from the aqueous polymerization
medium, but chitosan is a polycationic biopolymer, positive
charge PBCA-NPs may have been produced by coating them
with chitosan [40, 41].
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Figure 4: Agarose gel electrophoresis of NP/DNA complexes. Lane
1: DNA molecular weight marker; lane 2: naked plasmid DNA; lane
3: chitosan-coated PBCA-NPs; lanes 4–7 correspond to DNA with
progressively increasing proportions of NPs at the charge ratio of
5:1, 10:1, 15:1, and 30:1 (w/w), respectively.
In theory, more pronounced zeta potential values, being
positive or negative, tend to stabilize particle suspension
due to the electrostatic repulsion forces between particles
with the same electric charge prevents the aggregation of
the spheres [42]. Consequently, the presence of the positively
chargedgroupsontheparticlescouldleadtoelectricalcharge
interactions between the negatively charged surface cells and
the particles [43].
TEM images shown in Figure 3 reveal the surface mor-
phology and spherical shape of the prepared particles. The
actual diameter of the nanoparticles observed by TEM was
approximately 200nm and was found to be similar to the
values obtained by measurements based on light scattering.
The plasmid is protected from DNase degradation in this
formulation [44].
3.2. Complex Formation of PBCA-NPs With pEGFP-N1
Plasmid DNA. pDNA complex with previously prepared
nanoparticles was achieved by the formation of ion-pairs
between the positively charged amino groups located on theJournal of Biomedicine and Biotechnology 5
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Figure 5: Electrophoretic mobility analysis NP/DNA complexes
following DNase I digestion. Lane 1: EGFP-N1 plasmid DNA; lane
2: lane 1 + digestion; lane 3: NP/DNA complex at the charge of 5:1;
lane 4: lane 3 + digestion; lane 5: NP/DNA complex at the charge of
15:1; lane 6: lane 5 + digestion.
particle surface and the negatively charged phosphodiester
backbone of the plasmid DNA [45]. The electrophoretic
mobilityofDNA,complexwithPBCA-NPs,decreasesgradu-
allyontheagarosegelwithincreasingchargeratio(Figure 4).
However, in the control experiment, there was no DNA in
agarose gel. This method also allowed showing the depen-
dency of this interaction on pH, reﬂecting the deprotonation
of the modiﬁed silica particles at alkaline pH (data not
shown). The particle-DNA binding was also inhibited by the
presence of high salt concentrations (data not shown). This
suggests that this interaction is based on electrostatic forces,
resulting in interpolyelectrolyte complexes.
3.3. Enzyme Protection. Behr introduced the concept of
the “proton sponge” and hypothesized that polymers with
buﬀering capacities between 7.2 and 5.0 could buﬀer the
endosome and potentially induce its rupture [46]. As the
chitosan molecule is a weak base with a pKa value of
the D-glucosamine residue about 6.2–7.0 [47], we hypoth-
esize NP/DNA complexes formation can resist enzymatic
degradation. The results were analyzed by using agarose gel
electrophoresis. Figure 5 shows that free-plasmid DNA was
degraded completely into small fragments and could not be
visualized in the agarose gel, however, NP/DNA complexes
digested by DNase I were still visualized around the sample
pore.
3.4. Cytotoxicity Evaluation of NP/DNA Complexes. In vitro
toxicity of NP/DNA complexes was evaluated by MTT
assay in HepG2 cells using increasing doses of NPs. MTT
assay shows that the cytotoxicity of the NPs depended on
their concentration ranging from 0.1–8.0μg/μL( Figure 6).
The statistic analysis demonstrates that there are signiﬁcant
diﬀerences between concentrations (one-way ANOVA, P<
.001).ThesedatacanindicatethattheNPsbelow2μg/μLhad
little adverse eﬀect on the HepG2 cells viability, suggesting
that the doses of in vitro HepG2 cells uptake study less
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Figure 6: Cytotoxicity of cationic chitosan coated PBCA-NPs
analyzed by MTT assay, 24 hours posttreatment (n = 8). Columns,
mean; bars, SD, P<. 001 as evaluated by one-way ANOVA using
SPSS 17.0 version.
than 0.5μg/μL presented no toxicity. This is important
because most of the cationic polymers and lipids, which are
commonly used for gene transfection, have toxic eﬀects on
cellsatahigherconcentrationduetoelectrostaticinteraction
with negatively charged cellular membrane [48, 49]. Thus,
the PBCA-NPs is a promising carrier for gene delivery with
low cytotoxicity. However, its long-term in vivo toxicity and
immunogenicity should be further investigated.
3.5. Uptake of the Functionalized PBCA-NPs. In order to
study cellular uptake of NPs in vitro, the use of ﬂuorescently
orradioactivelylabeledNPsisthemostcommonexperimen-
tal approach found in the literature. Fluorescent labeling,
which we used the prepared ﬂuorescent positive PBCA-NPs
in this study, was chosen for the present study to avoid
exposure of the samples to radioactive materials. Fluorescent
labeling makes cellular uptake of NPs readily detectable by
ﬂuorescence microscopy. The extent of particle uptake can
then be determined by ﬂow cytometry. After incubation of
HepG2 cells with the ﬂuorescent PBCA-NPs for 6 hours,
the FACS measurements showed signiﬁcantly higher mean
ﬂuorescence intensity of 75.06% for cells incubated with the
positively charged ﬂuorescent PBCA-NPs with respect to the
control particles (see Figure 7).
Figure 8 shows ﬂuorescent microscopic images of HepG2
cell monolayers after the NPs uptake experiments, which
strongly support the previous quantitative measurements of
thecellularuptakeoftheNPsbyshowingstrongﬂuorescence
inthecell.However,noﬂuorescencecanbedetectedfromthe
image of the control cells.
3.6. In Vitro Gene Transfection and Expression in HepG2
Cells. In order to evaluate the eﬀe c to fP B C A - N P so n
transferring DNA, we investigated the transfection eﬃciency
of complexes containing pDNA in HepG2 cells to ﬁnd gene6 Journal of Biomedicine and Biotechnology
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Figure 7: (a) Quantitative analysis intracellular ﬂuorescence of HepG2 cells; (b) endocytosised with ﬂuorescent chitosan-coated PBCA-NPs
by ﬂow cytometry.
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Figure 8: Biocompatibility of functionalized chitosan-coated
PBCA-NPs (×200). (a) HepG2 cell endocytosised ﬂuorescent
chitosan-coated PBCA-NPs; (b) HepG2 cell without ﬂuorescent
chitosan-coated PBCA-NPs.
expression level. The concentration of PBCA-NPs used in
this experiment was much less than 0.5μg/μL, which would
not aﬀect the cell viability obviously according to the result
mentioned in cell viability assay.
The pictures of ﬂuorescence microscope to detect the
green ﬂuorescence sent out by transfected cells indicated rel-
ativelyhighertransfectioneﬃcienciesofNP/DNAcomplexes
(Figure 9(a)). To determine the gene transfer capability
of NPs in vitro exactly, ﬂow cytometry experiments were
conducted to determine the EGFP transfection levels in
HepG2cells.Itwasfoundthatthetransgeneexpressionlevels
increased with the time, and reached a climax at 72 hours,
then decreased. The results of the complexes are fused with
cell membrane easily through electrostatical interaction can
be explained by the fact that complexes possess the positive
potential in neutral conditions.
4. Conclusions
From these investigations, it is evident that this method
forms uniform cationic PBCA nanospheres which can bind
DNA readily by electrostatic interaction. Chitosan cannot
only chemically couple to PBCA giving the net positive
surface charge, but also produced particles with uniform
size and spherical shape, as observed by TEM. By applying
emulsion polymerization technique, it is possible to prepare
ﬂuorescent dye labeled PBCA-NPs. In the present study, we
identify that chitosan-coated PBCA-NPs are positive charge
and can be used as nonviral carrier for gene transfection.
Compared with negatively charged NPs, positively
charged NP/DNA complexes might prevent destabilization
by cation adsorption, give a better controlled release of
plasmid, favorably interact with negatively charged tissues
and provide site-speciﬁc target in vivo. Therefore, positively
charged targeting gene delivery vehicles may be considered
as very promising gene carriers for various administration
routes.Journal of Biomedicine and Biotechnology 7
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Figure 9: (a) Qualitative evaluation of EGFP-N1 transgene expression in HepG2 cells with chitosan-coated PBCA-NPs, ﬂuorescent image
(×200) of the cells was obtained after 96 hours upon incubation. (b) Quantitative evaluation of EGFP-N1 transgene expression in HepG2
cells as a function of time measured by ﬂow cytometric analysis with chitosan-coated PBCA-NPs. HepG2 cells without any treatment were
used as control.8 Journal of Biomedicine and Biotechnology
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